Enodia launched by Argobio and the Institut Pasteur

French biotech start-up studio Argobio and non-profit biomedical research center the Institut Pasteur have announced the launch of Enodia Therapeutics.

The new biotech company is focused on blocking and degrading disease-causing proteins for treating cancer, inflammatory diseases and viral infections.

Yves Ribeill, chief executive of Enodia, said: “With the convergence of an unprecedented diverse set of small molecules inhibitors of the Sec61/translocon molecular complex and advancements in generative AI, our vision is to develop novel small molecules drugs with good pharmaceutical properties that could overcome the most critical limitations of today’s medicines.”